---
title: "Dark Matter Bio Longevity Fund II"
description: "Extending Human Healthspan Through Breakthrough Biotechnology"
author: "Dark Matter"
date: "2025-11-25"
tags: ["investment", "longevity", "biotech", "fund"]
coverImage: "/share-banners/shareBanner__Dark-Matter-Bio_Longevity-Fund-II.webp"
shareImage: "/share-banners/shareBanner__Dark-Matter-Bio_Longevity-Fund-II.webp"
---

# Dark Matter Bio Longevity Fund II

*Extending Human Healthspan Through Breakthrough Biotechnology*

**$100M Target** | Seed to Series A/B | Vintage 2025

---

## General Partners

- **Skinner Layne**
- **Mark Moline**
- **Anthony Borquez**
- **Thomas Vu**

Contact: fund@darkmatter.bio

---

## Executive Summary

**Mission:** Invest in biotech innovations targeting aging mechanisms to extend healthspan and combat age-related diseases.

- Projected IRR: **25-30%**
- Expected MOIC: **10x** over 10 years
- Portfolio: **25-30** high-impact longevity startups

---

## Why Now?

- Global aging population: **2B people over 60 by 2050**
- Breakthroughs in CRISPR, senolytics, and AI-driven drug discovery
- **$5B+** VC investment in longevity startups in 2024

*Join us to capture the $7T longevity economy.*

---

## The Problem: The Aging Crisis

**Challenge:** Age-related diseases cost **$1T+** annually in global healthcare

- Alzheimer's, cancer, cardiovascular disease, diabetes, renal failure
- Average healthspan (65 years) lags lifespan (80+ years)
- **20%** of U.S. population over 65 by 2030

**Opportunity:** Biotech solutions can extend healthspan, reduce costs, and improve lives.

---

## Market Opportunity

**Total Addressable Market:** $600B+ by 2030

- **Therapeutics:** $200B (senolytics, gene therapies, novel molecules)
- **Diagnostics:** $100B (aging biomarkers, predictive testing)
- **Platforms:** $150B (AI drug discovery, practice management)

**15% CAGR** in longevity biotech through 2035

---

## Investment Thesis

**Core Belief:** Targeting the hallmarks of aging unlocks multi-disease therapies.

**Focus Areas:**
- Cellular rejuvenation (stem cell, exosome therapies)
- Precision medicine (genomic diagnostics, gene therapies)
- AI-driven drug discovery

---

## Our Differentiation

- Deep scientific expertise in longevity biology
- Proprietary deal flow via **Stanford, Cedars-Sinai** partnerships
- Relationships with longevity leaders: Ben Greenfield, Bryan Johnson, Peter Attia
- Focus on **IP-protected, scalable solutions**

---

## Exit Potential

- IPOs in public markets
- Acquisitions by big pharma
- Example: Pfizer's 2024 acquisition of a senolytics startup

---

## Fund Strategy

**Fund Size:** $100M | **Term:** 10 years

**Fees:** 2% management, 20-25% carried interest

**Geography:** 70% U.S./Europe, 30% global

**Stages:** Seed (50%), Series A/B (30%), Follow-ons (20%)

---

## Investment Approach

1. **25 primary investments**
2. **$2.75M - $3.0M** initial checks
3. **$5M - $10M** reserved for top performers
4. Follow-on allocation:
   - Top 3-5 companies: $5M-$10M+ total
   - Next 8-10: $3M-$5M total
   - Rest: pro-rata only

---

## Track Record: MarsBio Fund I

**Performance:**
- **5.2x MOIC**
- **419% net IRR**
- $60,000 distribution, 1 exit

---

## Portfolio Highlights

| Company | Stage | Valuation | Initial Investment |
|---------|-------|-----------|-------------------|
| AmberCycle | Series B | $270M | $2.5M |
| MiniCircle | Series B | $200M | $2.5M |
| Encellin | Series B | $100M | $20M |
| Inaru | Series B | $100M | $4M |

---

## Team: General Partners

**Mark Moline** - 15 years in VC, multiple exits, 6x unicorn investor

**Anthony Borquez** - Two-time exited founder, USC professor

**Skinner Layne** - Biotech VC experience

**Thomas Vu** - Investment expertise

---

## Advisory Board

**Dr. Keith Black** - Chairman, Cedars-Sinai Neurological Sciences Dept.

**Dr. Michael Snyder** - Chairman, Stanford Genetics Department

**Dr. Bruce Johnson** - Mayo Clinic

---

## Competitive Positioning

**DMBL Fund II vs. Peers**

- **Specialized focus** on biotech vs. broader AgeTech
- **Proprietary deal flow** from academic partnerships
- **First-mover** in emerging longevity sub-sectors
- Underfunded gaps: non-pharma interventions (nutraceuticals)

---

## Financial Projections

**Base Case:**
- Net IRR: **25-30%**
- MOIC: **10x** over 10 years
- Deployment: $80M over 3-4 years

**Exit Scenarios:** 50% IPOs, 40% acquisitions, 10% other

---

## Sensitivity Analysis

| Scenario | MOIC |
|----------|------|
| Conservative | 3x |
| Base Case | 10x |
| Optimistic | 12x |

---

## Risks

- **Scientific:** Clinical trial failures (30% fail Phase II)
- **Regulatory:** Delays in FDA/EMA approvals
- **Market:** Economic downturns impacting biotech funding

---

## Risk Mitigations

- Rigorous due diligence by scientific advisors
- Diversified portfolio across sub-sectors
- Staged investments to limit exposure

---

## Sustainability & Impact

**Mission:** Make longevity therapies accessible and equitable

**Impact Goals:**
- Add **10+ healthy years** to global lifespans
- Reduce **$1T healthcare burden** from age-related diseases

*Supports UN SDG #3: Good Health and Well-Being*

---

## Call to Action

**Join Us:** Invest in DMBL Fund II to shape the future of longevity

**Minimum Commitment:** $5M

**Deadlines:**
- Carry discount: December 31, 2025
- Full carry: March 2026

---

## Contact Us

**Schedule a meeting:**
- mark@darkmatter.bio
- skinner@darkmatter.bio

Due diligence materials available for qualified investors.

*Together, we can redefine aging.*

---

## Appendix: Market Data

**Sources:**
- McKinsey: $600B longevity biotech market by 2030
- WHO: 2B people over 60 by 2050
- PitchBook: $5B VC investment in longevity (2024)

**Additional Stats:**
- 15% CAGR in longevity biotech
- 50% increase in FDA fast-tracked longevity drugs (2023-2025)

---

## Legal Disclaimers

Past performance is not indicative of future results. Investments involve risks, including loss of capital.

**Accredited Investors Only:** DMBL Fund II is open to qualified investors per SEC regulations.

**Confidentiality:** This deck is for intended recipients only; do not distribute.
